You can add Paris-based Ipsen to the list of discount buyers patrolling the penny stock pack for a cheap M&A deal. The French biotech, which has had plenty of its own problems to grapple with, has swo …
Ipsen snags an approved cancer drug in $247M M&A deal as another battered biotech sells cheap
Ipsen snags an approved cancer drug in $247M M&A deal as another battered biotech sells cheap
Leave a reply